JNJ vs TSLA: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Tesla, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-22.
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
VS
Tesla, Inc. · Consumer Cyclical
$387.51
-45.0% upside to fair value
Grade D
QuantHub Verdict
JNJ has more upside to fair value
(+10.8%).
JNJ trades at a lower forward P/E
(26.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
TSLA |
| Current Price |
$230.69 |
$387.51 |
| Fair Value Estimate |
$255.61 |
$213.13 |
| Upside to Fair Value |
+10.8%
|
-45.0%
|
| Market Cap |
$555.9B |
$1,454.1B |
| Forward P/E |
26.8x
|
330.0x
|
| EV / EBITDA |
18.5x
|
122.9x
|
| Price / Sales |
5.8x
|
15.3x
|
| Price / FCF |
28.2x
|
233.8x
|
| Revenue Growth YoY |
+9.9%
|
-3.1%
|
| Gross Margin |
69.1%
|
18.0%
|
| Operating Margin |
26.9%
|
4.6%
|
| Return on Equity |
26.5%
|
4.8%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.54%
|
0.43%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Tesla, Inc. is a leading global manufacturer of electric vehicles, energy storage, and solar products, led by CEO Elon Musk since 2008. The company has a mixed business quality profile with a strong brand and innovation leadership but faces significant challenges including declining automotive revenue, which fell nearly 10% year-over-year in 2025, and a 3.1% revenue decline in the most recent qua…
Accumulation Zones
| Metric |
JNJ |
TSLA |
| Zone Low |
$191.71 |
$159.85 |
| Zone High |
$217.27 |
$181.16 |
| In Buy Zone? |
No
|
No
|